psalexa
logo

Neisseria Gonorrhoeae Infections Therapeutics Pipeline Analysis

Neisseria Gonorrhoeae Infections Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11280
Available Format:

Neisseria gonorrhoeae infections is a sexually transmitted disease that is caused by Neisseria gonorrhoeae bacterium which cause infections in throat, rectum, and genitals. In men, the observed symptoms of gonorrhoeae infections are burning sensation during urination, painful and swollen testicles, and white, green or yellow discharge from the penis. In women, the observed symptoms of gonorrhoeae are vaginal bleeding during periods, increased vaginal discharged, and burning sensation during urination. The unprotected vaginal, oral or anal sex are the risk factors for gonorrhoeae infections. Entasis Therapeutics, Inc. is in the process of developing ETX0914 as a bacterial type II topoisomerases inhibitor, for the treatment of gonorrhoeae infections. Therapyx, Inc. is also in the process of developing IL12 NanoCap for the treatment of gonorrhoeae infection. Some of the companies having the pipeline of neisseria gonorrhoeae infections include Therapyx, Inc., Entasis Therapeutics, Inc., and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry